US › Healthcare

Harmony Biosciences Holdings (HRMY)

US · Healthcare · Biotechnology

$38.78+8.93%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

$215.4M

Revenue YoY

+16.6%

Net profit

$32.5M

Profit YoY

-28.7%

EPS

$0.79

EPS estimate

$0.93

Net margin

15.1%

EPS came in at 0.79 against a street estimate of 0.93 — a miss of 15.1%.

Key statistics

Market cap

$2.04B

P/E

14.2

Forward P/E

10.6

P/B

2.24

Book value

$15.73

EPS (TTM)

$2.48

52-week high

$40.87

52-week low

$25.52

50-day MA

$34.31

200-day MA

$33.04

Beta

0.94

Analyst view

Analysts rate Harmony Biosciences Holdings a buy (8 buy, 0 hold, 1 sell out of 9) with an average price target of $45.50.

Shareholding

Insiders

11.70%

Institutions

102.82%

Largest institutional holders

Fund	Stake
BlackRock Inc	12.21%
FMR Inc	5.45%
Vanguard Portfolio Management, LLC	4.69%
American Century Companies Inc	3.64%
Vanguard Capital Management, LLC	3.63%
Dimensional Fund Advisors, Inc.	3.59%
LSV Asset Management	3.50%
SG Americas Securities, LLC	3.49%

Recent filings & reports

Document	Date
Results announced · Q3 2026	2026-07-16
Shareholder vote results · Q2 2026	2026-05-14
Results announced · Q2 2026	2026-05-07
Quarterly report · Q1 2026	2026-05-07
Board / officer change · Q2 2026	2026-04-14
Proxy statement · Q2 2026	2026-04-03
Annual report FY2025	2026-02-24
Quarterly report · Q3 2025	2025-11-04

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Harmony Biosciences Holdings — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.